Cardiovascular disease and cardiac biomarkers

Partner with the pioneers for earlier, more confident clinical decision-making.

Worldwide, over 30% of all deaths are attributable to cardiovascular disease (CVD).¹ In the UK alone, CVD affects around seven million people and is responsible for one in four premature deaths. ² The increasing incidence and high healthcare costs associated with CVDs require a holistic approach to prevention, early detection & treatment and monitoring of disease progression. Used in conjunction with clinical information, cardiac biomarkers are crucial to support an early and accurate diagnosis.^3-6

Roche has been the pioneer in in vitro diagnostic tests for CVD decision making for over 30 years. As a market leader in cardiac biomarkers,⁷ Roche offers diagnostic tests for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF) to support early clinical decision making, improved patient management, and increased efficiency & cost management.